Hikma enters the French generic injectables market, expanding European presence

London, 13 June 2022 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, is pleased to announce the establishment of Hikma France S.A.S. (Hikma France). This marks Hikma’s official entry into France, which has the second largest pharmaceutical market in Europe and a generic injectables hospital market of approximately $2 billion .

Press Release Corporate 13 June 2022

To date, Hikma has supplied 21 generic injectable medicines to hospitals in France through a third-party. Following the approval of Hikma France and the opening of a new commercial office outside Paris, it will now supply medicines to hospitals directly. This broadened portfolio will span several therapeutic areas including anti-infective, cardiovascular and central nervous system.

Hikma has an established and growing presence in Europe with high-quality manufacturing plants in Portugal, Italy and Germany, supplying injectable products to North America, the Middle East and North Africa and Europe.

Riad Mishlawi, President of Hikma Injectables commented:

“The expansion into France is an important step forward in our European growth ambition. Hikma France will complement our existing presence in Europe. I am excited by the opportunity to supply French hospitals and their patients with high-quality and affordable injectable medicines. We look forward to building our presence here as we aim to become a key player in the French hospital market.”

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.